Fabrizio Nelli

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

N/A

0Author DataRank · unranked

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “A Phase II Study of Cetuximab/Irinotecan in Patients with Heavily Pretreated Metastatic Colorectal Cancer: Predictive Value of Early Specific Toxicities”.

A Phase II Study of Cetuximab/Irinotecan in Patients with Heavily Pretreated Metastatic Colorectal Cancer: Predictive Value of Early Specific Toxicities

Clinical Colorectal Cancer(2008)10.3816/ccc.2008.n.035

N/A

0.330DataRank · unranked

8 citations

Fabrizio Nelli, Giovanni Cianci, Giulia Grassi, Luca Moscetti, Isabella Sperduti +5 more

Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study

Cancers(2025)10.3390/cancers17121948

N/A

0.269DataRank · unranked

5 citations

Enzo Maria Ruggeri, Antonella Virtuoso, Diana Giannarelli, Armando Raso, Fabrizio Chegai +4 more